As such the HPV antigens E6 and E7 are high on the priority-ranked list of cancer vaccine target antigens[7] In previously described clinical trials applying adoptive transfer of melanoma specific CD8+ T cells, no objective clinical responses were found in melanoma patients while melanoma specific CD8+ T cells were highly reactive against tumor cells in vitro[8]. This evidence concerns the gene CD8A and melanoma.